Features | Partner Sites | Information | LinkXpress
Sign In
Biostrata Ltd on behalf of Thermo
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Thermo Fisher Scientific Acquisition Augments Specialty Diagnostics Portfolio

By Labmedica International staff writers
Posted on 08 Sep 2009
Thermo Fisher Scientific Inc. (Waltham, MA, USA) signed a definitive agreement to acquire B.R.A.H.M.S. AG (Hennigsdorf, Germany) for US$478.8 million. B.R.A.H.M.S. will be integrated into the specialty diagnostics business within Thermo Fisher's analytical technologies segment. The transaction, which is subject to regulatory approvals, is expected to close in late September 2009.

B.R.A.H.M.S. is a provider of specialty in vitro diagnostic (IVD) tests based on biomarkers for sepsis, cardiovascular and pulmonary diseases, intensive care treatments, and prenatal screening. It also offers diagnostic tests and instrumentation for thyroid, prenatal, autoimmune, and oncology screening in both laboratory and point-of-care settings. The company's best-known product is Procalcitonin (PCT), a biomarker for the diagnosis and treatment of sepsis, a condition in which the patient's bloodstream is overwhelmed by bacterial infection.

The PCT test has become the gold standard in Europe for early diagnosis of sepsis, which is critical for patient survival, and the subsequent monitoring of treatment. The European testing model will be replicated in the United States where around 750,000 cases occur each year, one third of which are fatal.

Marijn E. Dekkers, president and CEO of Thermo Fisher Scientific, commented, "B.R.A.H.M.S. assays and instrumentation are a strong complement to our existing products for immunoassay testing, and its robust R&D pipeline creates promising opportunities to commercialize new patented diagnostic tests. In addition, the company gives us a significant reagent manufacturing footprint in Europe, while allowing us to leverage our deep customer access in the U.S. to market innovative new B.R.A.H.M.S. products, such as PCT and others now in development. This acquisition reinforces our strategy of building on our leadership in niche specialty diagnostics markets.”

Thermo Fisher Scientific Inc. supplies and serves hospitals and clinical diagnostic labs, pharmaceutic and biotechnology companies, universities, research institutions and government agencies, as well as environmental and industrial process control settings. The company has two brands, Thermo Scientific and Fisher Scientific. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables, and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies, and services used in healthcare, scientific research, safety, and education.

Related Links:

Thermo Fisher Scientific Inc.
B.R.A.H.M.S. AG



CELLAVISION AB
EUROIMMUN AG
KARL HECHT GMBH & CO KG
WATERS CORPORATION

Channels

Clinical Chemistry

view channel
Image: The Avance III 600 spectrometer for proton nuclear magnetic resonance analysis (Photo courtesy of Bruker).

New Blood Test Can Predict Future Breast Cancer

The analysis of a blood sample could predict if a woman will get breast cancer within two to five years which could create a paradigm shift in early diagnosis of this malignant neoplasm as well as other diseases.... Read more

Genetic Tests

view channel

Buccal Swabs Replace Phlebotomy for Postnatal and Pediatric DNA Collection

Collection of samples for prenatal and pediatric DNA sequencing procedures is now available via buccal swabs rather than by phlebotomy. CombiMatrix Corporation (Irvine, CA, USA) a molecular diagnostics company specializing in DNA-based diagnostic services for prenatal, postnatal, and pre-implantation genetic testing... Read more

Hematology

view channel
Image: QuantiTect Reverse Transcription Kit (Photo courtesy of Qiagen).

Independent Prognostic Factor for Acute Myeloid Leukemia Discovered

Acute myeloid leukemia (AML) is a clonal disorder involving a hierarchy of leukemic cells, and with investigations of the mechanism of AML, many epigenetically-regulated genes have been approved as new... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.